Francesca Barone
Chief Tech/Sci/R&D Officer presso CANDEL THERAPEUTICS, INC.
Patrimonio netto: 294 918 $ in data 31/03/2024
Profilo
Francesca Barone is currently the Chief Scientific Officer at Candel Therapeutics, Inc. She previously worked as the Director-laboratories at the Institute of Translational Medicine.
From 2010 to 2019, she was an Associate Professor at the University of Birmingham.
In 2019, she became the Head-Experimental Medicine at Senda Biosciences, Inc. Dr. Barone holds a doctorate degree from Sapienza University of Rome and King's College London.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 28/11/2023 | 186 657 ( 0.65% ) | 294 918 $ | 31/03/2024 |
Posizioni attive di Francesca Barone
| Società | Posizione | Inizio |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
Precedenti posizioni note di Francesca Barone
| Società | Posizione | Fine |
|---|---|---|
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/11/2020 |
| University of Birmingham | Corporate Officer/Principal | 01/05/2019 |
| Institute of Translational Medicine | Corporate Officer/Principal | - |
Formazione di Francesca Barone
| Sapienza University of Rome | Doctorate Degree |
| King's College London | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
| Institute of Translational Medicine |
- Borsa valori
- Insiders
- Francesca Barone
